Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/53268
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLinnebjerg, H.en
dc.contributor.authorPark, S.en
dc.contributor.authorKothare, P.en
dc.contributor.authorTrautmann, M.en
dc.contributor.authorMace, K.en
dc.contributor.authorFineman, M.en
dc.contributor.authorWilding, I.en
dc.contributor.authorNauck, M.en
dc.contributor.authorHorowitz, M.en
dc.date.issued2008en
dc.identifier.citationRegulatory Peptides, 2008; 151(1-3):123-129en
dc.identifier.issn0167-0115en
dc.identifier.issn1873-1686en
dc.identifier.urihttp://hdl.handle.net/2440/53268-
dc.description.abstractOBJECTIVES: To evaluate the effect of exenatide on gastric emptying (GE) in type 2 diabetes using scintigraphy. METHODS: Seventeen subjects with type 2 diabetes participated in a randomized, single-blind, 3-period, crossover study. In each 5-day period, 5 or 10 microg exenatide or placebo was administered subcutaneously BID. Oral antidiabetic treatments were continued. The presence of cardiac autonomic neuropathy was assessed during screening. On day 5, after the morning dose, subjects consumed a 450-kcal breakfast containing (99m)Tc-labeled eggs and (111)In-labeled water, and GE was measured by scintigraphy. Plasma glucose and insulin, perceptions of appetite, and plasma exenatide were also quantified. RESULTS: Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)]. GE was not different between subjects with cardiac autonomic neuropathy (n=7), compared with those without (n=10) (P>/=0.68). Exenatide reduced postprandial glucose (area under the curve [AUC((0-6 h))]) by 69-76% and peak insulin (C(max)) by 84-86% compared with placebo. There was an inverse relationship between the postprandial rise in glucose (AUC((0-3 h))) and GE (solid T(50), r=-0.49, P<0.001). CONCLUSIONS: Exenatide slows GE substantially in type 2 diabetes, which could be an important mechanism contributing to the beneficial effect of exenatide on postprandial glycemia.en
dc.description.statementofresponsibilityHelle Linnebjerg, Soomin Park, Prajakti A. Kothare, Michael E. Trautmann, Kenneth Mace, Mark Fineman, Ian Wilding, Michael Nauck and Michael Horowitzen
dc.language.isoenen
dc.publisherElsevier Science BVen
dc.subjectDiabetes; Gastric emptying; Exenatide; Scintigraphyen
dc.titleEffect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetesen
dc.typeJournal articleen
dc.identifier.rmid0020083668en
dc.identifier.doi10.1016/j.regpep.2008.07.003en
dc.identifier.pubid41261-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.